Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis
- 30 December 2025
- journal article
- abstracts
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 89 (6) , 14-20
Abstract
Differentiation of high-grade gliomas (WHO grades III and IV) is still a pressing issue despite advances of molecular biology in tumor stratification. Even with a comprehensive approach to differential diagnosis, uncertainty sometimes arises in classifying a glioma into a particular grade. This can complicate prognosis and selection of appropriate treatment. Objective. To develop an effective method for differentiating high-grade gliomas based on marker gene expression analysis. Material and methods. We analyzed expression of 31 marker genes in high-grade glioma samples (Grade III and IV) diagnosed with isocitrate dehydrogenase (IDH)-mutated oligodendroglioma, IDH-mutated astrocytoma and IDH-wildtype glioblastoma. Real-time polymerase chain reaction was used. Spearman rank correlation method was applied to select genes whose expression was most closely related to glioma grade. Gene expression and their ratios were compared in groups of Grade III and IV malignant gliomas using the Mann-Whitney test. Results. Expression ratios of three genes (CD44, CIRBP, and SOX2) were selected to assess malignancy grade. Expression ratios for these genes distinguishes IDH wild-type glioblastomas from IDH-mutated astrocytomas and oligodendrogliomas. They also have a stronger correlation with glioma grade than expression of each individual marker gene. Conclusion. Original method based on marker gene expression ratios does not replace standard diagnostic protocols, but may be an additional tool for optimized diagnostic process. This approach will be valuable to minimize errors and personalize therapeutic strategies. The last one is critical for prognosis.Keywords
This publication has 10 references indexed in Scilit:
- Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?Current Oncology Reports, 2024
- The Impact of DAXX, HJURP and CENPA Expression in Uveal Melanoma Carcinogenesis and Associations with Clinicopathological ParametersBiomedicines, 2024
- Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expressionBurdenko's Journal of Neurosurgery, 2023
- AKR1B1 Represses Glioma Cell Proliferation through p38 MAPK-Mediated Bcl-2/BAX/Caspase-3 Apoptotic Signaling PathwaysCurrent Issues in Molecular Biology, 2023
- MELK is a prognostic biomarker and correlated with immune infiltration in gliomaFrontiers in Neurology, 2022
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019Neuro-Oncology, 2022
- Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastomaCancer Cell International, 2022
- Expression and prognostic characteristics of m5C regulators in low‐grade gliomaJournal of Cellular and Molecular Medicine, 2021
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Prognostic Significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, Four New Markers in High-Grade GliomasPLOS ONE, 2013